Medivir 2023 Annual Report published
Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the company’s website: www.medivir.com. In the fall of 2023, very promising data from the ongoing phase 1b/2a study with Medivir's spearhead project fostrox in combination with Lenvima[®] were presented. The combination has shown continued improved clinical benefit in patients with advanced primary liver cancer (HCC) and at ASCO-GI in January 2024, data were presented showing further increases in the proportion of patients achieving a clinically relevant reduction